Purpose To evaluate the efficacy of intravitreal bevacizumab injection (IVB) for the treatment of chronic, recurrent, or atypical central serous chorioretinopathy (CSC). Methods Forty‐nine eyes of 49 patients who were diagnosed with chronic, recurrent, or atypcial CSC and treated with intravitreal injection of 1.25 mg/0.05 ml bevacizumab, were included for this retrospective study. Best‐corrected visual acuity (BCVA) and central macular thickness (CMT) were analyzed at baseline, 3, 6, 9, and 12 months after initial IVB. Results Patients received the mean of 2.16±1.34 IVB during the mean follow‐up period of 11.8±7.4 months, and 20.4% of patients had recurrent episode after initial resolution of subretinal fluid in this period. The mean baseline BCVA was 0.27±0.26 logarithm of minimum angle of resolution, and the mean baseline CMT was 353 ± 129 um. BCVA was significantly improved to 0.16 ± 0.18 (P = 0.005) and 0.14 ± 0.12 (P = 0.000) at 3 and 6 months, respectively. However, the improvement of BCVA was not significant at 9 months and 12 months. CMT was significantly reduced throughout the follow‐up period and 216±101 um (P = 0.008) at 12 months. Conclusion Intravitreal bevacizumab injection may be an effective treatment option for patients with chronic, recurrent, or atypical CSC. Further prospective, long‐term studies are warranted.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.